Companies › Novo Nordisk
37 active drug programs in 220 registered trials: 71 Phase 3, 54 Phase 1, 52 Phase 4, 43 Phase 2; Metabolic and endocrine, Cardiovascular, Hematology, Gastroenterology; next expected readout Dec 2026.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| Semaglutide Glucagon-like peptide 1 receptor agonist | GLP1R | Phase 4 | Obesity; Cardiovascular Risk; Cardiovascular Disease; Diabetes Mellitus, Type 2 … | Dec 2026 |
| Insulin icodec Insulin receptor agonist | INSR | Phase 4 | Diabetes Mellitus, Type 2; Diabetes Mellitus, Type 1 | Jan 2027 |
| Eptacog Alfa (Activated) Coagulation factor VII exogenous protein | F7 | Phase 4 | Severe Postpartum Haemorrhage | Aug 2027 |
| Liraglutide Glucagon-like peptide 1 receptor agonist | GLP1R | Phase 3 | Obesity; Type 2 Diabetes Patients; Atrial Fibrillation; Severe Obesity … | Dec 2026 |
| Somapacitan Growth hormone receptor agonist | GHR | Phase 3 | SGA, Turner Syndrome, Noonan Syndrome, ISS; SGA; Short Stature Children Born Small for Gestational Age (SGA) | Dec 2026 |
| Ziltivekimab Interleukin-6 inhibitor; Interleukin-6 binding agent | IL6 | Phase 3 | Heart Failure; Cardiovascular Risk; Myocardial Infarction | Jan 2027 |
| Cagrilintide B Dual GLP-1/glucagon receptor agonist | GLP1R, GCG, CALCR | Phase 3 | Obesity; Overweight; Cardiovascular Disease; Diabetes Mellitus, Type 2 | Jan 2027 |
| Concizumab Tissue factor pathway inhibitor inhibitor | TFPI | Phase 3 | Haemophilia A With Inhibitors; Haemophilia A Without Inhibitors; Haemophilia A and B With and Without Inhibitors | Feb 2027 |
| CagriSema Amylin and GLP-1 receptor agonist combination | GLP1R, CALCR | Phase 3 | Obesity; Diabetes Mellitus, Type 2; Overweight | Jun 2027 |
| Etavopivat Pyruvate kinase isozymes R/L activator | PKLR | Phase 3 | Sickle Cell Disease | Aug 2027 |
| NNC0487-0111 Mechanism unknown | – | Phase 3 | Obesity; Diabetes Mellitus; Overweight | Nov 2027 |
| NNC6019-0001 Unclear - mechanism not specified in registry text | – | Phase 3 | Transthyretin Amyloid Cardiomyopathy (ATTR CM) | Feb 2028 |
| Zenagamtide GLP-1/GIP receptor agonist | GLP1R, GIPR | Phase 3 | Overweight; Type 2 Diabetes | Jun 2028 |
| Denecimig (Mim8) Recombinant Factor VIII replacement | F8 | Phase 3 | Haemophilia A | Jun 2028 |
| NNC0662-0419 GLP-1 receptor agonist | – | Phase 2 | Overweight; Obesity; Diabetes Mellitus, Type 2 | Dec 2026 |
| CDR132L Antisense oligonucleotide targeting CAMKII delta | – | Phase 2 | Heart Failure; Healthy Volunteers | Dec 2026 |
| UBT251 GLP-1 receptor agonist | – | Phase 2 | Overweight; Diabetes Mellitus, Type 2; Obesity | Jan 2027 |
| NNC0519-0130 | – | Phase 2 | Chronic Kidney Disease | – |
| NNC0537-1482 | – | Phase 1 | Heart Failure | Jan 2027 |
| NNC4004-0002 Serum uric acid-lowering agent | – | Phase 1 | Healthy Volunteers | Jan 2027 |
| NNC6989-0001 | – | Phase 1 | Overweight | Jan 2027 |
| NNC0480-0389 GIP receptor agonist | GIPR | Phase 1 | Overweight | Jan 2027 |
| NNC0113-5840 | – | Phase 1 | Obesity | Jan 2027 |
| NNC0442-0344 A (Inno8) unclear - mechanism not specified for haemophilia A | – | Phase 1 | Haemophilia A | Feb 2027 |
| NNC4005-0001 | – | Phase 1 | Fatty Liver Disease | May 2027 |
| Coramitug Anti-transthyretin (TTR) monoclonal antibody; promotes removal of TTR amyloid deposits and | TTR | Phase 1 | Transthyretin Amyloid Cardiomyopathy | May 2027 |
| NNC0705-0002 Anti-inflammatory agent targeting heart and metabolic health | – | Phase 1 | Healthy Volunteers | Aug 2027 |
| NNC6022-0004 | – | Phase 1 | Obesity | Aug 2027 |
| NNC0642-1895 | – | Phase 1 | Healthy Volunteers | Sep 2027 |
| INV-347 | – | Phase 1 | Obesity | Sep 2027 |
| NNC0721-8060 | – | Phase 1 | Overweight | Sep 2027 |
| NNC0581-0001 | – | Phase 1 | Healthy Volunteers | Oct 2027 |
| NNC0638-0355 GLP-1 receptor agonist | – | Phase 1 | Obesity | Oct 2027 |
| NNC0497-0040 | – | Phase 1 | Type 1 Diabetes (T1D) | Feb 2028 |
| NNC9733-0001 GLP-1 receptor agonist | – | Phase 1 | Healthy Volunteer | Mar 2028 |
| NNC1679-0001 | – | Phase 1 | Healthy Volunteers | Jun 2028 |
| NNC0194-0499 | – | Phase 1 | Diabetes Mellitus, Type 1 | – |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT05567796 | Cagrilintide B | Phase 3 | Obesity | Metabolic and endocrine | Oct 2024 |
| NCT05567796 | Semaglutide | Phase 3 | Obesity | Metabolic and endocrine | Oct 2024 |
| NCT05567796 | CagriSema | Phase 3 | Obesity | Metabolic and endocrine | Oct 2024 |
| NCT03087032 | Liraglutide | Phase 4 | Type 2 Diabetes Patients | Metabolic and endocrine | Jan 2025 |
| NCT06410352 | Semaglutide | Phase 4 | Metabolic Syndrome | Metabolic and endocrine | Sep 2025 |
| NCT04873050 | Semaglutide | Phase 4 | Pre Diabetes | Metabolic and endocrine | Jan 2026 |
| NCT03899402 | Semaglutide | Phase 2 | Type 1 Diabetes Mellitus | Metabolic and endocrine | Jan 2026 |
| NCT06827002 | Semaglutide | Phase 1 | Obesity and Overweight | Metabolic and endocrine | Feb 2026 |
| NCT07374328 | Semaglutide | Phase 1 | Type 2 Diabetes | Metabolic and endocrine | May 2026 |
| NCT07272343 | Semaglutide | Phase 4 | Type 2 Diabetes Mellitus (T2DM) | Metabolic and endocrine | Jun 2026 |
| NCT05424003 | Semaglutide | Phase 2 | NAFLD | Gastroenterology | Aug 2026 |
| NCT06717698 | NNC0519-0130 | Phase 2 | Chronic Kidney Disease | Genitourinary | Sep 2026 |
| NCT07087795 | Semaglutide | Phase 1 | Diabetes Mellitus, Type 1 | Metabolic and endocrine | Sep 2026 |
| NCT07087795 | NNC0194-0499 | Phase 1 | Diabetes Mellitus, Type 1 | Metabolic and endocrine | Sep 2026 |
| NCT05119179 | Semaglutide | Phase 4 | PreDiabetes | Metabolic and endocrine | Oct 2026 |
| NCT07513168 | Semaglutide | Phase 4 | Obesity | Metabolic and endocrine | Dec 2026 |
| NCT05726227 | Semaglutide | Phase 3 | Obesity | Metabolic and endocrine | Dec 2026 |
| NCT07225816 | Liraglutide | Phase 1 | Obesity | Metabolic and endocrine | Dec 2026 |
| NCT07225816 | Semaglutide | Phase 1 | Obesity | Metabolic and endocrine | Dec 2026 |
| NCT07225816 | Semaglutide | Phase 1 | Obesity | Metabolic and endocrine | Dec 2026 |
| NCT07184632 | NNC0662-0419 | Phase 2 | Overweight | Metabolic and endocrine | Dec 2026 |
| NCT05195944 | Semaglutide | Phase 4 | Liver Transplant; Complications | Gastroenterology | Dec 2026 |
| NCT06396416 | Semaglutide | Phase 4 | Obesity | Genitourinary | Dec 2026 |
| NCT07059377 | Semaglutide | Phase 3 | Diabetes Mellitus, Type 2 | Psychiatry | Dec 2026 |
| NCT05067621 | Semaglutide | Phase 2 | Type 2 Diabetes Mellitus | Metabolic and endocrine | Dec 2026 |
| NCT03878446 | Somapacitan | Phase 2 | Short Stature Children Born Small for Gestational Age (SGA) | Other | Dec 2026 |
| NCT07223242 | Semaglutide | Phase 2 | HFpEF - Heart Failure With Preserved Ejection Fraction | Metabolic and endocrine | Dec 2026 |
| NCT05254314 | Semaglutide | Phase 2 | Asthma | Respiratory | Dec 2026 |
| NCT03856632 | Liraglutide | Phase 4 | Atrial Fibrillation | Cardiovascular | Dec 2026 |
| NCT05780905 | Semaglutide | Phase 4 | Diabetes Mellitus, Type 2 | Neurology | Dec 2026 |
| NCT06461377 | Semaglutide | Phase 4 | Type 2 Diabetes | Metabolic and endocrine | Dec 2026 |
| NCT06005012 | Semaglutide | Phase 2 | Fibrosis, Liver | Gastroenterology | Dec 2026 |
| NCT04451837 | Semaglutide | Phase 2 | Type2 Diabetes | Metabolic and endocrine | Dec 2026 |
| NCT05173714 | Semaglutide | Phase 2 | Chronic Kidney Diseases | Genitourinary | Dec 2026 |
| NCT07656454 | CDR132L | Phase 1 | Healthy Volunteers | Cardiovascular | Dec 2026 |
| NCT06200207 | Ziltivekimab | Phase 3 | Heart Failure | Cardiovascular | Jan 2027 |
| NCT07395687 | UBT251 | Phase 2 | Overweight | Metabolic and endocrine | Jan 2027 |
| NCT07029009 | Liraglutide | Phase 2 | Maturity Onset Diabetes of the Young | Metabolic and endocrine | Jan 2027 |
| NCT07297589 | Semaglutide | Phase 3 | STEMI - ST Elevation Myocardial Infarction | Cardiovascular | Jan 2027 |
| NCT06894784 | Semaglutide | Phase 3 | Diabetes Type 1 | Metabolic and endocrine | Jan 2027 |
| NCT06691243 | Semaglutide | Phase 2 | Cocaine Use Disorder | Infectious disease | Jan 2027 |
| NCT06387199 | Semaglutide | Phase 2 | Type 1 Diabetes | Metabolic and endocrine | Jan 2027 |
| NCT07218627 | NNC0537-1482 | Phase 1 | Heart Failure | Cardiovascular | Jan 2027 |
| NCT06859073 | NNC4004-0002 | Phase 1 | Healthy Volunteers | Metabolic and endocrine | Jan 2027 |
| NCT07437079 | NNC6989-0001 | Phase 1 | Overweight | Metabolic and endocrine | Jan 2027 |
| NCT07076199 | Insulin icodec | Phase 3 | Diabetes Mellitus, Type 1 | Metabolic and endocrine | Jan 2027 |
| NCT07411560 | Cagrilintide B | Phase 1 | Overweight | Metabolic and endocrine | Jan 2027 |
| NCT07411560 | NNC0480-0389 | Phase 1 | Overweight | Metabolic and endocrine | Jan 2027 |
| NCT06118281 | Ziltivekimab | Phase 3 | Cardiovascular Risk | Cardiovascular | Jan 2027 |
| NCT06937060 | Semaglutide | Phase 3 | Psoriasis (PsO) | Immunology | Jan 2027 |
| NCT07566390 | NNC0113-5840 | Phase 1 | Obesity | Metabolic and endocrine | Jan 2027 |
| NCT07220564 | NNC0442-0344 A (Inno8) | Phase 1 | Haemophilia A | Hematology | Feb 2027 |
| NCT04775082 | Liraglutide | Phase 3 | Obesity | Metabolic and endocrine | Feb 2027 |
| NCT07242534 | Semaglutide | Phase 4 | Infertility | Metabolic and endocrine | Feb 2027 |
| NCT07223983 | Semaglutide | Phase 1 | Alcohol Use Disorder | Metabolic and endocrine | Feb 2027 |
| NCT04083781 | Concizumab | Phase 3 | Haemophilia A With Inhibitors | Hematology | Feb 2027 |
| NCT07401992 | Semaglutide | Phase 4 | Psoriasis (PsO) | Metabolic and endocrine | Feb 2027 |
| NCT07011667 | Cagrilintide B | Phase 3 | Obesity | Metabolic and endocrine | Mar 2027 |
| NCT07011667 | Semaglutide | Phase 3 | Obesity | Metabolic and endocrine | Mar 2027 |
| NCT07314684 | Semaglutide | Phase 4 | T2DM (Type 2 Diabetes Mellitus) | Immunology | Mar 2027 |
The 60 nearest readouts of 220 trials; the rest in the app.
Cash of 26.5bn DKK on 2025-12-31; operating cash flow positive
Held by 4 of the 39 life-science funds Phaseline follows through their 13F filings. Who holds what.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.